Nuvectis Pharma (NASDAQ:NVCT - Free Report ) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.
Get Nuvectis Pharma alerts:
Sign Up
Nuvectis Pharma Stock Performance NVCT traded down $0.76 on Wednesday, hitting $6.43. 182,961 shares of the company were exchanged, compared to its average volume of 99,952. The stock's fifty day moving average is $8.17 and its 200-day moving average is $8.21. The company has a market cap of $118.13 million, a PE ratio of -4.50 and a beta of 0.45. Nuvectis Pharma has a 12 month low of $5.92 and a 12 month high of $18.65.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report ) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). As a group, equities research analysts expect that Nuvectis Pharma will post -1.52 EPS for the current fiscal year.
Insider Buying and Selling In other Nuvectis Pharma news, CEO Ron Bentsur purchased 5,000 shares of the business's stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $10.29 per share, with a total value of $51,450.00. Following the acquisition, the chief executive officer now directly owns 3,242,484 shares of the company's stock, valued at approximately $33,365,160.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . 38.85% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Nuvectis Pharma Several institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio boosted its stake in Nuvectis Pharma by 178.6% in the 3rd quarter. Strs Ohio now owns 3,900 shares of the company's stock valued at $50,000 after purchasing an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma during the first quarter worth $118,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Nuvectis Pharma in the fourth quarter valued at about $160,000. Finally, Baldwin Brothers LLC MA grew its stake in shares of Nuvectis Pharma by 22.0% in the fourth quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company's stock valued at $1,185,000 after acquiring an additional 25,660 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company's stock.
Nuvectis Pharma Company Profile (
Get Free Report )
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Articles Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
